MTOR and breast cancer: Several studies, combining inhibitors of RET and mTOR signaling (e.g., everolimus) have shown increased or prolonged benefit over single agents in thyroid and breast cancer models (Plaza-Menacho et al., 2010; Gild et al., 2013; Subbiah et al., 2015).